BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()

Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Xing, Jieyu, Lin, Limin, Li, Jing, Liu, Jiayu, Zhou, Changhua, Pan, Haitao, Shu, Rui, Dong, Bin, Cao, Donglin, Li, Qing, Wang, Zhong
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2017
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548338/
https://ncbi.nlm.nih.gov/pubmed/28797938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.07.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars